Bladder cancer Cell Models for Research

Bladder cancer is the 10th most common cancer worldwide, with approximately 573,000 new cases and 213,000 deaths in 2020 (WHO GLOBOCAN). The highest incidence rates are in Southern and Western Europe, North America, and Northern Africa. Major risk factors include tobacco smoking, occupational exposure to aromatic amines, chronic bladder inflammation, and certain genetic syndromes. The 5-year survival rate for localized bladder cancer is about 70%, but for metastatic disease it drops to around 5% (NCI SEER). Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate, while muscle-invasive bladder cancer (MIBC) has a poor prognosis, highlighting the need for better models to study progression and therapeutic response.

Bladder cancer is an excellent model for studying tumor heterogeneity and molecular subtypes. It is characterized by two main pathways: the papillary (low-grade) and non-papillary (high-grade) pathways, which are driven by distinct genetic alterations. Public datasets such as TCGA and COSMIC provide extensive genomic and transcriptomic data, enabling researchers to identify driver mutations and potential therapeutic targets. Open questions include the mechanisms of resistance to BCG therapy and immune checkpoint inhibitors, and the role of cancer stem cells in recurrence. Gene-edited cell models are essential for functional validation of these findings.

Bladder cancer arises from urothelial cells and progresses through two main pathways:

1. Papillary pathway (low-grade):

• • Activation of FGFR3 mutations (often in combination with HRAS mutations) leads to constitutive activation of the RAS-MAPK pathway.
• • Loss of chromosome 9q (e.g., CDKN2A deletion) is an early event.
• • These tumors are typically non-invasive but can recur.

2. Non-papillary pathway (high-grade):

• • Inactivation of TP53 and RB1 tumor suppressors is common.
• • Mutations in chromatin remodeling genes (ARID1A, KDM6A) are frequent.
• • These tumors are more aggressive and invasive.

Additionally, alterations in the PI3K/AKT/mTOR pathway (e.g., PIK3CA mutations) and the Wnt/β-catenin pathway contribute to tumor progression.

Data from TCGA PanCancer Atlas and COSMIC.

Key signaling networks deregulated in bladder cancer:

• • RAS-MAPK pathway: Activated by FGFR3 and HRAS mutations, leading to increased cell proliferation.
• • PI3K/AKT/mTOR pathway: Activated by PIK3CA mutations and loss of PTEN, promoting cell survival and growth.
• • p53/RB1 pathway: Inactivated by TP53 and RB1 mutations, leading to uncontrolled cell cycle progression and genomic instability.
• • Wnt/β-catenin pathway: Often dysregulated, contributing to epithelial-mesenchymal transition and invasion.
• • Chromatin remodeling: Mutations in ARID1A and KDM6A affect gene expression and differentiation.

These pathways are interconnected, and their crosstalk contributes to tumor heterogeneity and therapeutic resistance.

Organoids derived from patient tumors recapitulate the heterogeneity of bladder cancer and are useful for drug testing. They can be established from both NMIBC and MIBC, and maintain the genetic alterations of the original tumor. However, organoids are more complex to maintain and less amenable to high-throughput screens compared to 2D cell lines.

• • Patient-derived xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice. They preserve the tumor microenvironment and are useful for drug efficacy studies.
• • Genetically engineered mouse models (GEMM): Conditional knockouts of tumor suppressors (e.g., Tp53, Pten) or expression of oncogenes (e.g., FGFR3 mutants) in urothelial cells. They allow study of tumor initiation and progression.
• • Chemically induced models: Administration of carcinogens (e.g., N-butyl-N-(4-hydroxybutyl)nitrosamine, BBN) to mice induces bladder cancer that mimics human disease.

These models are valuable but have limitations in recapitulating the full spectrum of human genetic alterations.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications. For bladder cancer, common models include:

• • TP53 knockout cell lines (e.g., T24 TP53-KO) to study loss-of-function effects.
• • FGFR3 S249C knock-in cell lines (e.g., RT4 FGFR3-S249C) to model oncogenic activation.
• • HRAS G12V knock-in lines to study RAS pathway activation.

These gene-edited models are commercially available and sequence-verified, ensuring reproducibility. They are essential for validating driver mutations, studying drug resistance, and developing targeted therapies. Using isogenic pairs (wild-type vs. edited) allows direct comparison of the impact of specific mutations.

Gene-edited cell lines are used to validate the functional role of genes identified in genomic studies. For example:

• • TP53 knockout in bladder cancer cells leads to increased proliferation and genomic instability, confirming its tumor suppressor role.
• • FGFR3 S249C knock-in cells show constitutive activation of the MAPK pathway and increased cell growth, validating its oncogenic function.
• • KDM6A knockout lines exhibit altered gene expression and differentiation, supporting its role as a tumor suppressor.

These models allow researchers to study the downstream effects of specific mutations in a controlled genetic background.

Isogenic cell line pairs are powerful tools for drug screening:

• • Compare the sensitivity of wild-type vs. mutant cells to targeted inhibitors (e.g., FGFR inhibitors in FGFR3-mutant cells).
• • Identify mechanisms of resistance by exposing cells to increasing drug concentrations and analyzing resistant clones.
• • Use CRISPR knockout libraries to identify genes whose loss confers resistance or sensitivity to drugs.

For example, FGFR3-mutant bladder cancer cells are more sensitive to FGFR inhibitors, and resistance can arise through secondary mutations or activation of bypass pathways.

CRISPR-based screens can identify synthetic lethal interactions and potential biomarkers:

• • Perform genome-wide CRISPR knockout screens in bladder cancer cell lines to identify genes essential for survival.
• • Compare screens in different genetic backgrounds to find context-specific dependencies.
• • Validate candidate biomarkers using isogenic cell lines and patient samples.

For example, TP53-mutant bladder cancer cells may be more dependent on certain DNA repair pathways, which could be targeted therapeutically.